News Interim report for 1H 2023 Please read the full announcement in PDF Attachment 2023_54_Q22023_CompanyAnnouncement Continue Reading Previous Novartis remibrutinib Phase III trials met their primary endpoints and showed rapid symptom control in chronic spontaneous urticariaNext Novozymes delivers results within expectations in the first half of 2023 and narrows the full year outlook Related Stories News 0G Positions as the Blockchain for AI Agents as Industry Moves Toward $1 Trillion Agentic AI Economy News Wingman P5 by Brook Gaming: True wireless & near-zero latency for native PS5, PS4 & PC gaming News GreenBanana SEO Ranked #1 in Best AI SEO Agency List News CrescitAI Unveils Revolutionary AI Voice Agents That Never Miss a Call News Snail Games Leverages GDC 2026 Momentum to Drive Portfolio Growth Through Steam Spring Sale 2026 Featuring ARK: Survival Ascended, Echoes of Elysium, and Bellwright News Airia Enables Enterprise-Grade Security for OpenClaw AI Agent Deployments
